Hepatitis C is not only a serious public health issue -- it's the most common chronic blood-borne infection in the U.S., affecting approximately 3.2 million Americans. This virus can damage the liver and lead to cirrhosis, end-stage liver disease and liver cancer. It’s known as the silent disease because of the lack of symptoms.
“Merck has been committed to helping those with viral hepatitis for more than 30 years, and we are proud to build on that legacy by supporting educational and awareness efforts we believe can play an important role in addressing this serious global public health issue,” said Jay Galeota, president, Hospital and Speciality Care, Merck. “Through our support of hepatitis C education, screening and research, we hope to have a meaningful and lasting impact on the community of those affected by the disease.”
Here’s how we’re helping:
Merck recently made a grant to The Fund for Public Health in New York for Check Hep C NYC, a community-based initiative that aims to provide prevention counseling, testing and resources to New Yorkers who are at risk for or affected by chronic hep C.
Funding was provided to the American Liver Foundation for development of Hepatitis C: Diagnosis, Treatment and Support – a program that will offer a patient hotline and a web-based micro-site to people diagnosed with hepatitis C. Support through these new channels includes education as well as information on risk factors and the ability to locate support and resources.
Working with OraSure Technologies, Merck has donated more than 11,000 rapid test kits to assist local organizations around the world who have sought assistance with ongoing screening efforts.
Visit this campaign website to learn more about what Gregg Allman, Natalie Cole and Merck all have in common.